• Je něco špatně v tomto záznamu ?

Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV1) in cystic fibrosis patients receiving ivacaftor treatment

B. Nagy, Z. Bene, Z. Fejes, SL. Heltshe, D. Reid, NJ. Ronan, Y. McCarthy, D. Smith, A. Nagy, E. Joseloff, G. Balla, J. Kappelmayer, M. Macek, SC. Bell, BJ. Plant, MD. Amaral, I. Balogh,

. 2019 ; 18 (2) : 271-277. [pub] 20180927

Jazyk angličtina Země Nizozemsko

Typ dokumentu klinická studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20025922

BACKGROUND: We have recently shown that human epididymis protein 4 (HE4) levels correlate with the severity of cystic fibrosis (CF) lung disease. However, there are no data on how HE4 levels alter in patients receiving CFTR modulating therapy. METHODS: In this retrospective clinical study, 3 independent CF patient cohorts (US-American: 29, Australian: 12 and Irish: 19 cases) were enrolled carrying at least one Class III CFTR CF-causing mutation (p.Gly551Asp) and being treated with CFTR potentiator ivacaftor. Plasma HE4 was measured by immunoassay before treatment (baseline) and 1-6 months after commencement of ivacaftor, and were correlated with FEV1 (% predicted), sweat chloride, C-reactive protein (CRP) and body mass index (BMI). RESULTS: After 1 month of therapy, HE4 levels were significantly lower than at baseline and remained decreased up to 6 months. A significant inverse correlation between absolute and delta values of HE4 and FEV1 (r = -0.5376; P < .001 and r = -0.3285; P < .001), was retrospectively observed in pooled groups, including an independent association of HE4 with FEV1 by multiple regression analysis (β = -0.57, P = .019). Substantial area under the receiver operating characteristic curve (ROC-AUC) value was determined for HE4 when 7% mean change of FEV1 (0.722 [95% CI 0.581-0.863]; P = .029) were used as classifier, especially in the first 2 months of treatment (0.806 [95% CI 0.665-0.947]; P < .001). CONCLUSIONS: This study shows that plasma HE4 levels inversely correlate with lung function improvement in CF patients receiving ivacaftor. Overall, this potential biomarker may be of value for routine clinical and laboratory follow-up of CFTR modulating therapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025922
003      
CZ-PrNML
005      
20201222160443.0
007      
ta
008      
201125s2019 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jcf.2018.08.013 $2 doi
035    __
$a (PubMed)30268371
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Nagy, Béla $u Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary. Electronic address: nagy.bela@med.unideb.hu.
245    10
$a Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV1) in cystic fibrosis patients receiving ivacaftor treatment / $c B. Nagy, Z. Bene, Z. Fejes, SL. Heltshe, D. Reid, NJ. Ronan, Y. McCarthy, D. Smith, A. Nagy, E. Joseloff, G. Balla, J. Kappelmayer, M. Macek, SC. Bell, BJ. Plant, MD. Amaral, I. Balogh,
520    9_
$a BACKGROUND: We have recently shown that human epididymis protein 4 (HE4) levels correlate with the severity of cystic fibrosis (CF) lung disease. However, there are no data on how HE4 levels alter in patients receiving CFTR modulating therapy. METHODS: In this retrospective clinical study, 3 independent CF patient cohorts (US-American: 29, Australian: 12 and Irish: 19 cases) were enrolled carrying at least one Class III CFTR CF-causing mutation (p.Gly551Asp) and being treated with CFTR potentiator ivacaftor. Plasma HE4 was measured by immunoassay before treatment (baseline) and 1-6 months after commencement of ivacaftor, and were correlated with FEV1 (% predicted), sweat chloride, C-reactive protein (CRP) and body mass index (BMI). RESULTS: After 1 month of therapy, HE4 levels were significantly lower than at baseline and remained decreased up to 6 months. A significant inverse correlation between absolute and delta values of HE4 and FEV1 (r = -0.5376; P < .001 and r = -0.3285; P < .001), was retrospectively observed in pooled groups, including an independent association of HE4 with FEV1 by multiple regression analysis (β = -0.57, P = .019). Substantial area under the receiver operating characteristic curve (ROC-AUC) value was determined for HE4 when 7% mean change of FEV1 (0.722 [95% CI 0.581-0.863]; P = .029) were used as classifier, especially in the first 2 months of treatment (0.806 [95% CI 0.665-0.947]; P < .001). CONCLUSIONS: This study shows that plasma HE4 levels inversely correlate with lung function improvement in CF patients receiving ivacaftor. Overall, this potential biomarker may be of value for routine clinical and laboratory follow-up of CFTR modulating therapy.
650    _2
$a dospělí $7 D000328
650    _2
$a aminofenoly $x terapeutické užití $7 D000627
650    _2
$a biologické markery $x analýza $7 D015415
650    _2
$a index tělesné hmotnosti $7 D015992
650    _2
$a dítě $7 D002648
650    _2
$a aktivátory chloridových kanálů $x terapeutické užití $7 D065101
650    12
$a cystická fibróza $x genetika $x patofyziologie $x terapie $7 D003550
650    _2
$a protein CFTR $x genetika $7 D019005
650    _2
$a monitorování léčiv $x metody $7 D016903
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a usilovný výdechový objem $x účinky léků $7 D005541
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mutace $7 D009154
650    _2
$a chinolony $x terapeutické užití $7 D015363
650    _2
$a respirační funkční testy $x metody $7 D012129
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a pot $x chemie $7 D013542
650    _2
$a protein WFDC2 $x analýza $7 D000081102
655    _2
$a klinická studie $7 D000068397
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Bene, Zsolt $u Department of Pediatrics, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
700    1_
$a Fejes, Zsolt $u Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
700    1_
$a Heltshe, Sonya L $u Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA.
700    1_
$a Reid, David $u QIMR Berghofer Medical Research Institute and The Prince Charles Hospital, Brisbane, Australia.
700    1_
$a Ronan, Nicola J $u Cork Adult Cystic Fibrosis Centre, Cork University Hospital, Cork, Ireland.
700    1_
$a McCarthy, Yvonne $u Cork Adult Cystic Fibrosis Centre, Cork University Hospital, Cork, Ireland.
700    1_
$a Smith, Daniel $u QIMR Berghofer Medical Research Institute and The Prince Charles Hospital, Brisbane, Australia.
700    1_
$a Nagy, Attila $u Department of Preventive Medicine, Faculty of Public Health, University of Debrecen, Debrecen, Hungary.
700    1_
$a Joseloff, Elizabeth $u Cystic Fibrosis Foundation, Bethesda, MD, USA.
700    1_
$a Balla, György $u Department of Pediatrics, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; MTA-DE Vascular Biology, Thrombosis and Hemostasis Research Group, Hungarian Academy of Sciences, Debrecen, Hungary.
700    1_
$a Kappelmayer, János $u Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
700    1_
$a Macek, Milan $u Department of Biology and Medical Genetics, Charles University and Motol University Hospital, Prague, Czech Republic.
700    1_
$a Bell, Scott C $u QIMR Berghofer Medical Research Institute and The Prince Charles Hospital, Brisbane, Australia.
700    1_
$a Plant, Barry J $u Cork Adult Cystic Fibrosis Centre, Cork University Hospital, Cork, Ireland.
700    1_
$a Amaral, Margarida D $u University of Lisboa, Faculty of Sciences, BioISI-Biosystems & Integrative Sciences Institute, Lisboa, Portugal.
700    1_
$a Balogh, István $u Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; Division of Clinical Genetics, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
773    0_
$w MED00006892 $t Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society $x 1873-5010 $g Roč. 18, č. 2 (2019), s. 271-277
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30268371 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222160439 $b ABA008
999    __
$a ok $b bmc $g 1600067 $s 1116608
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 18 $c 2 $d 271-277 $e 20180927 $i 1873-5010 $m Journal of cystic fibrosis $n J Cyst Fibros $x MED00006892
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace